A neomycin-resistant cell line for improved production of monoclonal antibodies to cell surface antigens.
Overgrowth of hybridomas by proliferating spleen T cells often hinders the production of monoclonal antibodies to certain antigens. To overcome this problem we derived neomycin-resistant fusion partner SP2 neoR.1 by transfection of SP2/0-Ag14 cells with plasmid pSVTK neo beta. Hybridomas obtained with SP2 neoR.1 grew optimally in the presence of the neomycin analog G418 at concentrations which blocked the proliferative response of T cells to mitogenic stimuli. The advantage of using SP2 neoR.1 and G418 under conditions where spleen cell proliferation occurs after fusion was demonstrated with hybridomas derived from a rat immunized with mouse helper T cell lines.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis*; D000954:Antigens, Surface / Q000276:immunology*; D002459:Cell Fusion / Q000379:methods; D002460:Cell Line; D004351:Drug Resistance; D006825:Hybridomas / Q000187:drug effects / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D009355:Neomycin / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D011917:Rats, Inbred Lew; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D009355:Neomycin